Products
Quetmolimab Biosimilar Monoclonal Antibody (CX3CL1) for Research
Pre-Made Quetmolimab biosimilar, Whole mAb, Anti-CX3CL1 Antibody: Anti-ABCD-3/C3Xkine/CXC3/CXC3C/NTN/NTT/SCYD1/fractalkine/neurotactin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-461-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Quetmolimab biosimilar, Whole mAb, Anti-CX3CL1 Antibody: Anti-ABCD-3/C3Xkine/CXC3/CXC3C/NTN/NTT/SCYD1/fractalkine/neurotactin therapeutic antibody |
| INN Name | Quetmolimab |
| Target | CX3CL1 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | KAN Research Institute;EA Pharma;Eisai Co Ltd |
| Conditions Approved | na |
| Conditions Active | Crohn's disease;Rheumatoid arthritis |
| Conditions Discontinued | Primary biliary cirrhosis |
| Development Tech | na |
About target - CX3CL1
1. Protein Fractalkine
2. Gene CX3CL1
3. Organism Homo sapiens (Human)
Function
Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1 (PubMed:9782118, PubMed:12055230, PubMed:23125415, PubMed:9931005, PubMed:21829356).
The CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:9024663, PubMed:9177350, PubMed:9782118, PubMed:12055230).
Regulates leukocyte adhesion and migration processes at the endothelium (PubMed:9024663, PubMed:9177350).
Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner (PubMed:23125415, PubMed:24789099).
In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins (PubMed:23125415, PubMed:24789099).
In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1 (PubMed:23125415, PubMed:24789099).
Processed fractalkine:
The soluble form is chemotactic for T-cells and monocytes, but not for neutrophils.
Fractalkine:
The membrane-bound form promotes adhesion of those leukocytes to endothelial cells.
